182 related articles for article (PubMed ID: 32293289)
1. The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease.
Trembling PM; Apostolidou S; Gentry-Maharaj A; Parkes J; Ryan A; Tanwar S; Burnell M; Harris S; Menon U; Rosenberg WM
BMC Gastroenterol; 2020 Apr; 20(1):104. PubMed ID: 32293289
[TBL] [Abstract][Full Text] [Related]
2. Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Trembling PM; Apostolidou S; Gentry-Maharaj A; Parkes J; Ryan A; Tanwar S; Burnell M; Jacobs I; Menon U; Rosenberg WM
BMC Public Health; 2017 Jun; 17(1):603. PubMed ID: 28659136
[TBL] [Abstract][Full Text] [Related]
3. Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS).
Trembling PM; Apostolidou S; Gentry-Maharaj A; Parkes J; Ryan A; Tanwar S; Burnell M; Menon U; Rosenberg WM
BMC Public Health; 2018 Mar; 18(1):409. PubMed ID: 29587697
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test.
Kim BK; Kim HS; Yoo EJ; Oh EJ; Park JY; Kim DY; Ahn SH; Han KH; Kim SU; Park YN
Hepatology; 2014 Dec; 60(6):1911-9. PubMed ID: 25142433
[TBL] [Abstract][Full Text] [Related]
5. The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.
Connoley D; Patel PJ; Hogan B; Tanwar S; Rhodes F; Parkes J; Burt A; Watkins J; Sievert W; Rosenberg W
BMC Gastroenterol; 2021 Jun; 21(1):268. PubMed ID: 34182924
[TBL] [Abstract][Full Text] [Related]
6. Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Fourkala EO; Burnell M; Cox C; Ryan A; Salter LC; Gentry-Maharaj A; Parmar M; Jacobs I; Menon U
BMJ Open; 2014 Sep; 4(9):e005400. PubMed ID: 25252818
[TBL] [Abstract][Full Text] [Related]
7. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.
Parkes J; Roderick P; Harris S; Day C; Mutimer D; Collier J; Lombard M; Alexander G; Ramage J; Dusheiko G; Wheatley M; Gough C; Burt A; Rosenberg W
Gut; 2010 Sep; 59(9):1245-51. PubMed ID: 20675693
[TBL] [Abstract][Full Text] [Related]
8. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease.
Irvine KM; Wockner LF; Shanker M; Fagan KJ; Horsfall LU; Fletcher LM; Ungerer JP; Pretorius CJ; Miller GC; Clouston AD; Lampe G; Powell EE
Liver Int; 2016 Mar; 36(3):370-7. PubMed ID: 26104018
[TBL] [Abstract][Full Text] [Related]
9. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.
Younossi ZM; Felix S; Jeffers T; Younossi E; Nader F; Pham H; Afendy A; Cable R; Racila A; Younoszai Z; Lam BP; Golabi P; Henry L; Stepanova M
JAMA Netw Open; 2021 Sep; 4(9):e2123923. PubMed ID: 34529067
[TBL] [Abstract][Full Text] [Related]
10. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.
Jacobs I; Gentry-Maharaj A; Burnell M; Manchanda R; Singh N; Sharma A; Ryan A; Seif MW; Amso NN; Turner G; Brunell C; Fletcher G; Rangar R; Ford K; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Scott I; Jenkins H; Mould T; Woolas R; Murdoch J; Dobbs S; Leeson S; Cruickshank D; Skates SJ; Fallowfield L; Parmar M; Campbell S; Menon U
Lancet Oncol; 2011 Jan; 12(1):38-48. PubMed ID: 21147030
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
[TBL] [Abstract][Full Text] [Related]
14. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
Rasmussen DN; Thiele M; Johansen S; Kjærgaard M; Lindvig KP; Israelsen M; Antonsen S; Detlefsen S; Krag A; ;
J Hepatol; 2021 Nov; 75(5):1017-1025. PubMed ID: 34118335
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
Seko Y; Kawanaka M; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Okanoue T; Itoh Y; Nakajima A;
J Gastroenterol Hepatol; 2022 Dec; 37(12):2313-2320. PubMed ID: 36198983
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
Thiele M; Madsen BS; Hansen JF; Detlefsen S; Antonsen S; Krag A
Gastroenterology; 2018 Apr; 154(5):1369-1379. PubMed ID: 29317276
[TBL] [Abstract][Full Text] [Related]
17. Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease.
Ouzan D; Penaranda G; Jlaiel M; Joly H; Corneille J
Sci Rep; 2024 May; 14(1):12198. PubMed ID: 38806580
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Bailey K; Ryan A; Apostolidou S; Fourkala E; Burnell M; Gentry-Maharaj A; Kalsi J; Parmar M; Jacobs I; Pikhart H; Menon U
BMC Public Health; 2015 Mar; 15():253. PubMed ID: 25848938
[TBL] [Abstract][Full Text] [Related]
19. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
20. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.
Pennisi G; Enea M; Romero-Gomez M; Viganò M; Bugianesi E; Wong VW; Fracanzani AL; Sebastiani G; Boursier J; Berzigotti A; Eslam M; Ampuero J; Benmassaoud A; La Mantia C; Mendoza YP; George J; Craxì A; Camma' C; de Ledinghen V; Petta S
Aliment Pharmacol Ther; 2022 Mar; 55(5):604-615. PubMed ID: 34988994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
